서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 6 of 6

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2019-02	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial Chung, Hyun Cheol; Arkenau, Hendrik-Tobias; Lee, Jeeyun; Rha, Sun Young; Oh, Do-Youn; Wyrwicz, Lucjan; Kang, Yoon-Koo; Lee, Keun-Wook; Infante, Jeffrey R.; Lee, Sung Sook; Kemeny, Margaret; Keilholz, Ulrich; Melichar, Bohuslav; Mita, Alain; Plummer, Ruth; Smith, Denis; Gelb, Arnold B.; Xiong, Huiling; Hong, Janet; Chand, Vikram; Safran, Howard Journal for ImmunoTherapy of Cancer, Vol.7 No.1, p. 30	DOI
2019-02	Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial Chung, Hyun Cheol; Arkenau, Hendrik-Tobias; Lee, Jeeyun; Rha, Sun Young; Oh, Do-Youn; Wyrwicz, Lucjan; Kang, Yoon-Koo; Lee, Keun-Wook; Infante, Jeffrey R; Lee, Sung Sook; Kemeny, Margaret; Keilholz, Ulrich; Melichar, Bohuslav; Mita, Alain; Plummer, Ruth; Smith, Denis; Gelb, Arnold B; Xiong, Huiling; Hong, Janet; Chand, Vikram; Safran, Howard Journal for ImmunoTherapy of Cancer. 2019 Feb 04;7(1):30	view file DOI
2023-06	Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. Meric-Bernstam, Funda; Makker, Vicky; Oaknin, Ana; Oh, Do Youn; Banerjee, Susana N.; Martin, Antonio Gonzalez; Jung, Kyung Hae; Lugowska, Iwona A.; Manso, Luis; Manzano, Aranzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Anoka, Chiedozie; Ma, Yan; Puvvada, Soham D.; Lee, Jung-Yun Journal of Clinical Oncology, Vol.41 No.17_SUPPL, pp.LBA3000-LBA3000	DOI
2024-01	Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial Meric-Bernstam, Funda; Makker, Vicky; Oaknin, Ana; Oh, Do-Youn; Banerjee, Susana; González-Martín, Antonio; Jung, Kyung Hae; Ługowska, Iwona; Manso, Luis; Manzano, Aránzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Fielding, Anitra; Ma, Yan; Puvvada, Soham; Shire, Norah; Lee, Jung-Yun Journal of Clinical Oncology, Vol.42 No.1, pp.47-58	DOI
2024-11	Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02 Oaknin, Ana; Lee, Jung-Yun; Makker, Vicky; Oh, Do-Youn; Banerjee, Susana; Gonzalez-Martin, Antonio; Jung, Kyung Hae; Lugowska, Iwona; Manso, Luis; Manzano, Aranzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Fielding, Anitra; Puvvada, Soham; Smith, Ann; Meric-Bernstam, Funda ADVANCES IN THERAPY, Vol.41 No.11, pp.4125-4139	DOI
2025-05	Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02 Oaknin, Ana; Lee, Jung-Yun; Makker, Vicky; Oh, Do-Youn; Banerjee, Susana; Gonzalez-Martin, Antonio; Jung, Kyung Hae; Lugowska, Iwona; Manso, Luis; Manzano, Aranzazu; Melichar, Bohuslav; Siena, Salvatore; Stroyakovskiy, Daniil; Fielding, Anitra; Puvvada, Soham; Smith, Ann; Meric-Bernstam, Funda ADVANCES IN THERAPY, Vol.42 No.5, pp.2015-2018	DOI

1